NeoStem raises $16.5M as it continues to shift its focus to cell therapy
This article was originally published in Scrip
Executive Summary
NeoStem, the New York-based cell therapy company, plans to raise $16.5 million through the sale of 13.8 million share-and-warrant units at $1.20 per unit, a considerable discount to the 18 July stock closing price of $1.32.